Aberrant regulation of Wnt signaling in hepatocellular carcinoma
- PMID: 27672271
- PMCID: PMC5011664
- DOI: 10.3748/wjg.v22.i33.7486
Aberrant regulation of Wnt signaling in hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in the world. Several signaling pathways, including the wingless/int-1 (Wnt) signaling pathway, have been shown to be commonly activated in HCC. The Wnt signaling pathway can be triggered via both catenin β1 (CTNNB1)-dependent (also known as "canonical") and CTNNB1-independent (often referred to as "non-canonical") pathways. Specifically, the canonical Wnt pathway is one of those most frequently reported in HCC. Aberrant regulation from three complexes (the cell-surface receptor complex, the cytoplasmic destruction complex and the nuclear CTNNB1/T-cell-specific transcription factor/lymphoid enhancer binding factor transcriptional complex) are all involved in HCC. Although the non-canonical Wnt pathway is rarely reported, two main non-canonical pathways, Wnt/planar cell polarity pathway and Wnt/Ca(2+) pathway, participate in the regulation of hepatocarcinogenesis. Interestingly, the canonical Wnt pathway is antagonized by non-canonical Wnt signaling in HCC. Moreover, other signaling cascades have also been demonstrated to regulate the Wnt pathway through crosstalk in HCC pathogenesis. This review provides a perspective on the emerging evidence that the aberrant regulation of Wnt signaling is a critical mechanism for the development of HCC. Furthermore, crosstalk between different signaling pathways might be conducive to the development of novel molecular targets of HCC.
Keywords: Canonical wingless/int-1 signaling; Catenin β1; Crosstalk; Hepatocellular carcinoma; Non-canonical wingless/int-1 signaling; Wingless/int-1.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Figures
Similar articles
-
Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317. World J Gastroenterol. 2015. PMID: 26034368 Free PMC article. Review.
-
Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus.Pol J Pathol. 2015 Mar;66(1):9-21. doi: 10.5114/pjp.2015.51148. Pol J Pathol. 2015. PMID: 26017875 Review.
-
Interplay of Wnt β-catenin pathway and miRNAs in HBV pathogenesis leading to HCC.Clin Res Hepatol Gastroenterol. 2019 Aug;43(4):373-386. doi: 10.1016/j.clinre.2018.09.012. Epub 2018 Oct 28. Clin Res Hepatol Gastroenterol. 2019. PMID: 30377095 Review.
-
Zinc finger transcription factor 191, directly binding to β-catenin promoter, promotes cell proliferation of hepatocellular carcinoma.Hepatology. 2012 Jun;55(6):1830-9. doi: 10.1002/hep.25564. Hepatology. 2012. PMID: 22213192
-
NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.Cancer Lett. 2016 Jun 28;376(1):10-21. doi: 10.1016/j.canlet.2016.03.006. Epub 2016 Mar 11. Cancer Lett. 2016. PMID: 26975630
Cited by
-
Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β-catenin signaling and tumor growth.Mol Oncol. 2023 Nov;17(11):2314-2336. doi: 10.1002/1878-0261.13520. Epub 2023 Sep 20. Mol Oncol. 2023. PMID: 37699867 Free PMC article.
-
Long non-coding RNA XIST promotes cell growth and metastasis through regulating miR-139-5p mediated Wnt/β-catenin signaling pathway in bladder cancer.Oncotarget. 2017 Oct 10;8(55):94554-94568. doi: 10.18632/oncotarget.21791. eCollection 2017 Nov 7. Oncotarget. 2017. Retraction in: Oncotarget. 2022 Nov 17;13:1258. doi: 10.18632/oncotarget.28314. PMID: 29212249 Free PMC article. Retracted.
-
Apolipoprotein E: A Potential Prognostic and Diagnostic Biomarker for Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2025 Feb 17;12:301-324. doi: 10.2147/JHC.S504078. eCollection 2025. J Hepatocell Carcinoma. 2025. PMID: 39991517 Free PMC article.
-
Safranal-loaded gold nanoparticles alleviate hepatocellular carcinoma via targeting the Wnt/β-catenin pathway.Discov Oncol. 2025 May 19;16(1):821. doi: 10.1007/s12672-025-02447-w. Discov Oncol. 2025. PMID: 40389761 Free PMC article.
-
Cryptolepine Suppresses Colorectal Cancer Cell Proliferation, Stemness, and Metastatic Processes by Inhibiting WNT/β-Catenin Signaling.Pharmaceuticals (Basel). 2023 Jul 19;16(7):1026. doi: 10.3390/ph16071026. Pharmaceuticals (Basel). 2023. PMID: 37513937 Free PMC article.
References
-
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
-
- Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol. 2016;51:473–486. - PubMed
-
- Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
